Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum

NCT01882504 is registered in ClinicalTrials.gov with XOMA (US) LLC as lead sponsor.

NCT NCT01882504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01882504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum
Lead sponsor
XOMA (US) LLC
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
October 31, 2015
Enrollment
8 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma gangrenosum